ENOV vs. ESTA, AVNS, SNN, MRUS, ACAD, OLK, CERT, TNDM, QDEL, and ACLX
Should you be buying Enovis stock or one of its competitors? The main competitors of Enovis include Establishment Labs (ESTA), Avanos Medical (AVNS), Smith & Nephew (SNN), Merus (MRUS), ACADIA Pharmaceuticals (ACAD), Olink Holding AB (publ) (OLK), Certara (CERT), Tandem Diabetes Care (TNDM), QuidelOrtho (QDEL), and Arcellx (ACLX). These companies are all part of the "medical" sector.
Establishment Labs (NASDAQ:ESTA) and Enovis (NYSE:ENOV) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, media sentiment, dividends, profitability and community ranking.
Establishment Labs received 88 more outperform votes than Enovis when rated by MarketBeat users. Likewise, 62.22% of users gave Establishment Labs an outperform vote while only 60.00% of users gave Enovis an outperform vote.
72.9% of Establishment Labs shares are owned by institutional investors. Comparatively, 98.5% of Enovis shares are owned by institutional investors. 11.4% of Establishment Labs shares are owned by insiders. Comparatively, 2.4% of Enovis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Enovis has a net margin of -4.51% compared to Enovis' net margin of -53.12%. Establishment Labs' return on equity of 3.98% beat Enovis' return on equity.
Establishment Labs presently has a consensus target price of $55.00, suggesting a potential downside of 1.72%. Enovis has a consensus target price of $75.43, suggesting a potential upside of 47.70%. Given Establishment Labs' higher probable upside, analysts clearly believe Enovis is more favorable than Establishment Labs.
In the previous week, Establishment Labs had 4 more articles in the media than Enovis. MarketBeat recorded 13 mentions for Establishment Labs and 9 mentions for Enovis. Enovis' average media sentiment score of 0.59 beat Establishment Labs' score of 0.50 indicating that Establishment Labs is being referred to more favorably in the media.
Establishment Labs has a beta of 1.23, suggesting that its share price is 23% more volatile than the S&P 500. Comparatively, Enovis has a beta of 1.99, suggesting that its share price is 99% more volatile than the S&P 500.
Enovis has higher revenue and earnings than Establishment Labs. Enovis is trading at a lower price-to-earnings ratio than Establishment Labs, indicating that it is currently the more affordable of the two stocks.
Summary
Enovis beats Establishment Labs on 10 of the 17 factors compared between the two stocks.
Get Enovis News Delivered to You Automatically
Sign up to receive the latest news and ratings for ENOV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ENOV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
